BERKELEY HEIGHTS, NJ - November 9, 2004
Conference Call and Webcast
The conference call can be accessed live at 8:30 AM EST this
morning as follows:
The conference call can be accessed live as follows:
U.S./Canada: Dial (877) 634-8606, reference Genta Incorporated.
International: Dial (706) 679-3140, reference Genta Incorporated.
The webcast will be available in the Investor Relations section of
the Company's website at:
http://www.genta.com/genta/InvestorRelation/events.html
and will be archived for 30 days.
About Genta
Genta Incorporated is a pharmaceutical company with a diversified
product portfolio that is focused on delivering innovative products
for the treatment of patients with cancer. The Company's research
platform is anchored by two major programs that center on
oligonucleotides (RNA and DNA-based medicines) and small molecules.
Genasense® (oblimersen sodium) Injection, the Company's lead
compound from its oligonucleotide program, is currently undergoing
late-stage, Phase 3 clinical testing. The leading drug in Genta's
small molecule program is Ganite® (gallium nitrate injection),
which the Company is exclusively marketing in the U.S. for
treatment of patients with cancer-related hypercalcemia that is
resistant to hydration. For more information about Genta, please
visit our website at:
http://www.genta.com/
.
This press release and the conference call to follow contain
forward-looking statements with respect to business conducted by
Genta Incorporated. By their nature, forward-looking statements and
forecasts involve risks and uncertainties because they relate to
events and depend on circumstances that will occur in the future.
There are a number of factors that could cause actual results and
developments to differ materially. For a discussion of those risks
and uncertainties, please see the Company's Annual Report/Form 10-K
for 2003.
SOURCE: Genta Incorporated
